Amylyx Pharmaceuticals Announces An Underwritten Public Offering Of Its Common Stock; Financial Terms Not Disclosed

Author: Benzinga Newsdesk | September 09, 2025 03:03pm

Amylyx Pharmaceuticals (NASDAQ:AMLX) Has Initiated An Underwritten Public Offering Of Its Common Stock, With All Shares Being Offered By The Company. The Underwriters Have A 30-day Option To Purchase Up To 15% Additional Shares. The Offering's Completion And Terms Remain Subject To Market Conditions.

Amylyx intends to use the net proceeds from this offering, together with existing cash, cash equivalents and marketable securities, for:

• Avexitide commercial readiness;
• Research and development; and
• Working capital and other general corporate purposes.

Leerink Partners and Guggenheim Securities are acting as lead bookrunning managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering.

The shares described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-285525) that was filed with the Securities and Exchange Commission (the "SEC") on March 4, 2025, and declared effective by the SEC on March 26, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may also be obtained by contacting: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, telephone: (212) 518-9544, email: GSEquityProspectusDelivery@guggenheimpartners.com.

Posted In: AMLX